In the last trading session, 1.48 million shares of the Akero Therapeutics Inc (NASDAQ:AKRO) were traded, and its beta was -0.22. Most recently the company’s share price was $51.15, and it changed around -$3.06 or -5.64% from the last close, which brings the market valuation of the company to $3.84B. AKRO currently trades at a discount to its 52-week high of $58.40, offering almost -14.17% off that amount. The share price’s 52-week low was $17.84, which indicates that the current value has risen by an impressive 65.12% since then. We note from Akero Therapeutics Inc’s average daily trading volume that its 10-day average is 3.29 million shares, with the 3-month average coming to 1.15 million.
Akero Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended AKRO as a Hold, whereas 9 deemed it a Buy, and 0 rated it as Underweight. Akero Therapeutics Inc is expected to report earnings per share of -1.12 for the current quarter.
Akero Therapeutics Inc (NASDAQ:AKRO) trade information
Instantly AKRO has showed a red trend with a performance of -5.64% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 57.78 on recent trading dayincreased the stock’s daily price by 11.47%. The company’s shares are currently up 83.86% year-to-date, but still down -5.01% over the last five days. On the other hand, Akero Therapeutics Inc (NASDAQ:AKRO) is 95.53% up in the 30-day period. We can see from the shorts that 3.35 million shares have been sold at a short interest cover period of 4.23 day(s).
The consensus price target as assigned by Wall Street analysts is $50, which translates to bulls needing to decrease their stock price by -2.3% from its current value. Analyst projections state that AKRO is forecast to be at a low of $50 and a high of $50.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 1.03%. Akero Therapeutics Inc earnings are expected to increase by -37.36% in 2025, but the outlook is negative -19.08% per year for the next five years.
AKRO Dividends
Akero Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Akero Therapeutics Inc (NASDAQ:AKRO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 5.12% of Akero Therapeutics Inc shares, and 98.03% of them are in the hands of institutional investors. The stock currently has a share float of 103.32%. Akero Therapeutics Inc stock is held by 255.0 institutions, with JANUS HENDERSON GROUP PLC being the largest institutional investor. By 2024-06-30, it held 11.5942% of the shares, which is about 6.88 million shares worth $161.28 million.
BLACKROCK INC., with 9.4197% or 5.59 million shares worth $131.06 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
